Biocryst Pharmaceuticals Inc BCRX
1 target with a reported result
Releases of the last 3 yearsThe numbers BCRX said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| Revenue Fiscal 2026 |
Given $625.00M to $645.00M release Jan 12, 2026
Kept $625.00M to $645.00M release Feb 26, 2026
Kept $625.00M to $645.00M release May 6, 2026
Kept $625.00M to $645.00M release Aug 5, 2026
Kept $625.00M to $645.00M release Nov 4, 2026
|
– | Not reported yet | |
The company's words–ORLADEYO net revenue expected to be between $625 million and $645 million in 2026– release Jan 12, 2026 —Maintained full year 2026 ORLADEYO revenue guidance between $625 and $645 million— release Feb 26, 2026 The company maintained its expectation for full year 2026 global net ORLADEYO revenue to be between $625 million and $645 million and for full year 2026 total revenue, including RAPIVAB (peramivir injection), to be between $635 million and $660 million. release May 6, 2026 — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million — release Aug 5, 2026 — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million — release Nov 4, 2026 | ||||
| Revenue Fiscal 2024 (ended Dec 31, 2024) |
Given $380.00M to $400.00M release Jan 8, 2024
Kept $380.00M to $400.00M release Feb 26, 2024
Raised $390.00M to $400.00M release May 6, 2024
Raised $420.00M to $435.00M release Aug 5, 2024
Raised $443.00M to $448.00M release Nov 4, 2024
|
$450.71M 10-K filed 2025-02-25 |
Above the range | |
The company's words—ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for $1 billion in peak sales— release Jan 8, 2024 —2024 ORLADEYO net revenue expected to be between $380-$400 million— release Feb 26, 2024 Based on the team’s success in accelerating ORLADEYO patients through the U.S. reauthorization process faster than anticipated, the company is adjusting its outlook for full year 2024 global net ORLADEYO revenue to be between $390 million and $400 million, the top end of its prior guidance range. release May 6, 2024 —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— release Aug 5, 2024 — Company introduces full-year 2024 total product revenue guidance of $443-$448 million based on additional 2024 revenue from RAPIVAB — release Nov 4, 2024 | ||||
| Revenue (company-defined) Fiscal 2024 (ended Dec 31, 2024) |
Given $390.00M to $400.00M release May 6, 2024
Raised $430.00M to $435.00M release Nov 4, 2024
|
– | No standard number | |
The company's words—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — release May 6, 2024 — Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) — release Nov 4, 2024 | ||||
1 target far from the company's reported total, so not compared (usually a target for one product, segment or definition)
- Revenue, Fiscal 2025 (ended Dec 31, 2025): said $590.00M to $600.00M, reported $874.84M. The company's words
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (16 releases since 2024-01-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BCRX/export.csv") into a cell.